Omega Therapeutics To Participate In Two Upcoming Investor Conferences
Omega Therapeutics (Nasdaq: OMGA) has announced its participation in two upcoming investor conferences. The company will engage in fireside chats at the Jefferies Global Healthcare Conference on June 6, 2024, at 9:30 a.m. ET, and the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, at 10:40 a.m. ET. Omega Therapeutics is a clinical-stage biotech company developing programmable epigenomic mRNA medicines for various diseases. The events will be webcast live on Omega’s investor relations website, with replays available for 90 days.
- Participation in high-profile investor conferences increases visibility.
- Management's engagement in fireside chats can boost investor confidence.
- Live webcasts and replays available, enhancing accessibility and transparency.
- Focus on innovative epigenomic mRNA medicines offers a unique market position.
- Pipeline includes diverse therapeutic candidates targeting oncology, regenerative medicine, inflammatory, and cardiometabolic conditions.
- No new financial or clinical data disclosed in the announcement.
- Potential for increased scrutiny from investors and analysts.
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in fireside chats at two upcoming investor conferences.
Jefferies Global Healthcare Conference
Date: Thursday, June 6, 2024
Time: 9:30 a.m. ET
Goldman Sachs 45th Annual Global Healthcare Conference
Date: Monday, June 10, 2024
Time: 10:40 a.m. ET
Live webcasts of the fireside chats will be available on the Investors section of the Company's website at www.omegatherapeutics.com. Archived replays will be available on the same website for approximately 90 days.
About Omega Therapeutics
Omega Therapeutics is a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines to treat or cure a broad range of diseases. By pre-transcriptionally modulating gene expression, Omega’s approach enables precision epigenomic control of nearly all human genes, including historically undruggable and difficult-to-treat targets, without altering native nucleic acid sequences. Founded in 2017 by Flagship Pioneering following breakthrough research by world-renowned experts in the field of epigenetics, Omega is led by a seasoned and accomplished leadership team with a track record of innovation and operational excellence. The Company is committed to revolutionizing genomic medicine and has a pipeline of therapeutic candidates derived from its OMEGA platform spanning oncology, regenerative medicine, and multigenic diseases including inflammatory and cardiometabolic conditions.
For more information, visit omegatherapeutics.com, or follow us on X and LinkedIn.
FAQ
When is Omega Therapeutics attending the Jefferies Global Healthcare Conference?
What time is Omega Therapeutics' fireside chat at the Goldman Sachs Healthcare Conference?
Where can I watch the live webcasts of Omega Therapeutics' investor conferences?
How long will the replays of Omega Therapeutics' conference participation be available?
What is the Nasdaq ticker symbol for Omega Therapeutics?
What type of medicines is Omega Therapeutics developing?
What therapeutic areas does Omega Therapeutics' pipeline cover?
